Page 6 - Cipla

Cipla Health signs agreement, strengthens beauty play with Ivia's brands

Cipla Health strengthens beauty play in Tier II-VI towns with Ivia Beaute's cosmetics, personal care distribution and marketing biz

Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr

Pharma major Cipla Ltd will acquire the cosmetics and personal care distribution and marketing business of Ivia Beaute Pvt Ltd, including the latter's brands Astaberry, Ikin and Bhimsaini, on a worldwide basis for Rs 130 crore, according to a regulatory filing by the company. Cipla Health Ltd (CHL), a wholly owned subsidiary and consumer healthcare arm, has signed a Business Transfer Agreement (BTA) for purchase of the distribution and marketing business undertaking of the cosmetics and personal care business of Ivia Beaute Pvt Ltd, Cipla said. This strategic move is aligned with Cipla's focus on enhancing its consumer healthcare and wellness portfolio, it added. The acquisition will include Ivia Beaute's brands namely Astaberry, Ikin and Bhimsaini on a worldwide basis, the company said. On the cost of acquisition, Cipla said it will be "Rs 130 crore on the closing date and Rs 110 crore contingent upon achievement of certain financial parameters (milestones) for next 3 years as ...

Stocks to Watch today: Jio Financial, Cipla, Vi, Brigade, Vedanta, Aster DM

Stocks to watch on Tuesday, April 16, 2024: Balrampur Chini, Bandhan Bank, Exide, GNFC, Hind Copper, India Cement, Metropolis, National Aluminium, PEL, SAIL and Zee are the 11 stocks in F&O ban today.

MNCs partner Indian firms to boost market reach in pharmaceutical sector

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

Big plans ahead: Cipla looks for shot in the arm in niche areas

Open to licensing, collaboration in anti-diabetes space

Cipla receives approval from drug regulator CDSCO for UTI drug

Plazomicin is a new intravenous (IV) aminoglycoside that has demonstrated efficacy and safety in clinical trials compared to meropenem (antibacterial agent)

Market resilience in a pill: Pharma's formula for Q3 earnings upgrades

Rx for returns: Pharma firms' dominance in market recovery prescription

Cipla eyes acquisitions, inorganic partnerships in US, European markets

Drug major Cipla is eyeing acquisitions and inorganic partnerships in the US market while consolidating its presence across segments in the domestic market. The Mumbai-based company is also looking to improve the top line in Europe and margin expansion in South Africa. "Product launches through delisting strategy and as well as inorganic partnerships and acquisitions will remain one of our key priorities for the US market," Cipla Global Chief Financial Officer Ashish Adukia said in an analyst call. The drug maker would also focus on commercial execution of existing portfolios and resolution of USFDA observations, he added. In the South African market, Cipla would build on its performance aided by growth in private and select tender business with greater emphasis on margin expansion, Adukia stated. "In emerging markets and Europe, top priority is to improve top line while margins are maintained at sustainable levels," he said. As per the yearly trend, the fourth quarter will have

Launch delays key risk to outlook for pharma company Cipla stock

The company reported a 13.7 per cent increase in sales to Rs 6,603 crore led by 11.5 per cent growth in the India business

Battle shifts to new class of drugs in diabetes treatment in India

Glenmark Pharmaceuticals launched a biosimilar version of liraglutide earlier this month, after getting the nod from the Drugs Controller General of India (DCGI)

Cipla board rejig: Samina Hamied to step down from executive role

Balram Bhargava appointed as independent director on board

Stocks to Watch today: Zee, Cipla, MRPL, Axis Bank, Medi Assist, JSW Group

Stocks to watch on Tuesday, January 23, 2024: Zee Entertainment in focus as Sony India calls-off merger; Axis Bank, Havells, JSW Energy, L&T Housing Finance, RECL and Tata Elxsi to Q3 results today.

Cipla's net profit jumps 32% to Rs 1,055.9 crore in third quarter

Cipla advanced its board meeting to January 22 to approve its results for the quarter and nine months ended December 31, 2023, to avoid confusion following an alleged social media leak

Cipla Q3 results: Profit rises 32% to Rs 1,056 crore, beats estimates

The Mumbai-based company had posted a consolidated net profit of Rs 801 crore in the year-ago period, Cipla Ltd said in a statement

Cipla forges strategic partnership for global cell therapy advancements

The collaborative effort is aimed at developing and commercialising novel Cell therapy products for critical unmet medical needs in the US, Japan, and the EU

Cipla invests Rs 42 crore in GoApptiv to enhance healthcare access

Cipla's move aligns with its vision to strengthen investments in channels and technologies

Stocks to Watch: Mazagon Dock, Tata Motors, REC, Blue Dart, Cipla, Lloyd

Stocks to Watch on December 11, 2023: REC has signed a 200-million-euro loan agreement with the German bank KfW to enhance the distribution infrastructure of discoms

Warning Letter for Pithampur SEZ facility remains an overhang for Cipla

While some brokerages believe that the issue could escalate and be detrimental for Cipla, others believe that the Warning Letter was on expected lines and the impact may not be meaningful

Cipla's Pithampur unit gets USFDA warning; analysts remain bullish

On Monday, Cipla share price dropped 0.21 per cent, ending the day's trade at Rs 1,246 apiece on the BSE

Stocks to Watch: L&T, Bharti Airtel, SBI Card, Dixon, Cipla, Bajaj Finance

Stocks to watch on November 20, 2023: SBI Card said that its capital adequacy ratio is expected to decline by 4 per cent due to the RBI's latest move on tightening consumer loan norms